Literature DB >> 17534929

Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies.

Tino Schenk1, Sven Stengel, Stefanie Goellner, Daniel Steinbach, Hans Peter Saluz.   

Abstract

The preferentially expressed antigen of melanoma (PRAME) is expressed at high levels in large fractions of human malignancies, e.g., acute myeloid leukemia. Therefore, PRAME is an important marker for diagnosis of various malignant diseases and a relevant parameter for monitoring minimal residual disease. It is supposed to be involved in tumorigenic processes. Because of these important aspects we investigated its transcriptional regulation in detail. Most relevant was a detailed DNA methylation analysis of the PRAME 5' region by genomic sequencing in correlation with PRAME expression in various human patient samples and cell lines. In combination with DNA-truncation/transfection experiments with respect to DNA methylation, we show that changes in the methylation pattern in defined parts of the regulatory regions of PRAME are sufficient for its upregulation in cells usually not expressing the gene. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17534929     DOI: 10.1002/gcc.20465

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  20 in total

1.  PRAME expression in hairy cell leukemia.

Authors:  Evgeny Arons; Tara Suntum; Inger Margulies; Constance Yuan; Maryalice Stetler-Stevenson; Robert J Kreitman
Journal:  Leuk Res       Date:  2008-03-04       Impact factor: 3.156

Review 2.  DNA hypomethylation in the origin and pathogenesis of human diseases.

Authors:  Igor P Pogribny; Frederick A Beland
Journal:  Cell Mol Life Sci       Date:  2009-03-27       Impact factor: 9.261

3.  Opposing roles of Dnmt1 in early- and late-stage murine prostate cancer.

Authors:  Shannon R Morey Kinney; Michael T Moser; Marien Pascual; John M Greally; Barbara A Foster; Adam R Karpf
Journal:  Mol Cell Biol       Date:  2010-06-28       Impact factor: 4.272

4.  The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters.

Authors:  Adalberto Costessi; Nawel Mahrour; Esther Tijchon; Rieka Stunnenberg; Marieke A Stoel; Pascal W Jansen; Dotan Sela; Skylar Martin-Brown; Michael P Washburn; Laurence Florens; Joan W Conaway; Ronald C Conaway; Hendrik G Stunnenberg
Journal:  EMBO J       Date:  2011-08-05       Impact factor: 11.598

5.  Methylation pattern of preferentially expressed antigen of melanoma in acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Ya-Zhen Qin; Yan-Huan Zhang; Xiao-Ying Qin; Hong-Hu Zhu
Journal:  Oncol Lett       Date:  2017-02-28       Impact factor: 2.967

Review 6.  Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia.

Authors:  Frances Wadelin; Joel Fulton; Paul A McEwan; Keith A Spriggs; Jonas Emsley; David M Heery
Journal:  Mol Cancer       Date:  2010-08-27       Impact factor: 27.401

7.  Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.

Authors:  Stine H Kresse; Halfdan Rydbeck; Magne Skårn; Heidi M Namløs; Ana H Barragan-Polania; Anne-Marie Cleton-Jansen; Massimo Serra; Knut Liestøl; Pancras C W Hogendoorn; Eivind Hovig; Ola Myklebost; Leonardo A Meza-Zepeda
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

8.  NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.

Authors:  Seth M Pollack; Yonqing Li; Megan J Blaisdell; Erik A Farrar; Jeffrey Chou; Benjamin L Hoch; Elizabeth T Loggers; Eve Rodler; Janet F Eary; Ernest U Conrad; Robin L Jones; Cassian Yee
Journal:  PLoS One       Date:  2012-02-27       Impact factor: 3.240

Review 9.  PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions.

Authors:  Cecilia Lezcano; Achim A Jungbluth; Klaus J Busam
Journal:  Surg Pathol Clin       Date:  2021-04-28

10.  Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells.

Authors:  Stefanie Kewitz; Martin S Staege
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.